New York, USA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Pruritus Pipeline Analysis Demonstrates 27+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight Pruritus is also known as itching, which is an…
Portland, OR, Sept. 09, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global pruritus therapeutics market generated $7.9 billion in 2021 and is estimated to hit $11.2 billion by 2031,…
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieved on the WI-NRS…
ROCKVILLE, Md., June 21, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today launched a new education and awareness campaign that will raise awareness of pruritus and help people with chronic kidney disease-associated pruritus…
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022…
Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patientsEuropean…
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with…
Los Angeles, USA , July 13, 2021 (GLOBE NEWSWIRE) -- Uremic Pruritus Pipeline Shows Rapid Progress in Clinical Trials Around 6+ key companies are developing Uremic Pruritus therapies. The drug candidate Difelikefalin by Cara…